ATE227584T1 - Untereinheitsimpfstoff gegen flavivirus infektion - Google Patents

Untereinheitsimpfstoff gegen flavivirus infektion

Info

Publication number
ATE227584T1
ATE227584T1 AT96917828T AT96917828T ATE227584T1 AT E227584 T1 ATE227584 T1 AT E227584T1 AT 96917828 T AT96917828 T AT 96917828T AT 96917828 T AT96917828 T AT 96917828T AT E227584 T1 ATE227584 T1 AT E227584T1
Authority
AT
Austria
Prior art keywords
virus
glycoprotein
proteins
retain
membrane
Prior art date
Application number
AT96917828T
Other languages
English (en)
Inventor
John M Ivy
Eileen Nakano
David Clements
Original Assignee
Hawaii Biotech Group
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hawaii Biotech Group filed Critical Hawaii Biotech Group
Application granted granted Critical
Publication of ATE227584T1 publication Critical patent/ATE227584T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/116—Togaviridae (F); Matonaviridae (F); Flaviviridae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT96917828T 1995-05-24 1996-05-24 Untereinheitsimpfstoff gegen flavivirus infektion ATE227584T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US44873495A 1995-05-24 1995-05-24
US48880795A 1995-06-07 1995-06-07
US50046995A 1995-07-10 1995-07-10
PCT/US1996/007627 WO1996037221A1 (en) 1995-05-24 1996-05-24 Subunit vaccine against flavivirus infection

Publications (1)

Publication Number Publication Date
ATE227584T1 true ATE227584T1 (de) 2002-11-15

Family

ID=27412379

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96917828T ATE227584T1 (de) 1995-05-24 1996-05-24 Untereinheitsimpfstoff gegen flavivirus infektion

Country Status (10)

Country Link
US (1) US6165477A (de)
EP (1) EP0836482B1 (de)
AT (1) ATE227584T1 (de)
AU (1) AU716676B2 (de)
CA (1) CA2224724C (de)
DE (1) DE69624815T2 (de)
DK (1) DK0836482T3 (de)
ES (1) ES2184869T3 (de)
PT (1) PT836482E (de)
WO (1) WO1996037221A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6074865A (en) * 1995-07-20 2000-06-13 The United States Of America As Represented By The Secretary Of The Army Recombinant dengue virus DNA fragment
CU22666A1 (es) * 1996-11-25 2001-04-27 Inst De Medicina Tropical Pedro Kouri Procedimiento para la expresión de genes de los virus del dengue en la levadura pichia pastoris, adns recombinantes y microorganismos transformados
AU2002300271B8 (en) * 1997-07-31 2006-08-10 Hawaii Biotech, Inc. Recombinant dimeric envelope vaccine against flaviviral infection
WO1999006068A2 (en) * 1997-07-31 1999-02-11 Hawaii Biotechnology Group, Inc. Recombinant dimeric envelope vaccine against flaviviral infection
FR2767324B1 (fr) * 1997-08-14 2001-04-06 Pasteur Institut Utilisation de proteines d'enveloppe recombinantes pour le diagnostic du virus de la dengue
US6541011B2 (en) 1998-02-11 2003-04-01 Maxygen, Inc. Antigen library immunization
US7227011B2 (en) * 1998-06-04 2007-06-05 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Nucleic acid vaccines for prevention of flavivirus infection
CA2331368C (en) * 1998-06-04 2009-02-10 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nucleic acid vaccines for prevention of flavivirus infection
US6416763B1 (en) 1998-08-28 2002-07-09 Hawaii Biotechnology Group, Inc. Recombinant nonstructural protein subunit vaccine against flaviviral infection
US6432411B1 (en) 1999-07-13 2002-08-13 Hawaii Biotechnology Group Recombinant envelope vaccine against flavivirus infection
US7094411B2 (en) 2000-02-16 2006-08-22 The United States Of America As Represented By The Department Of Health And Human Services Avirulent, immunogenic flavivirus chimeras
EP1272215B1 (de) * 2000-04-14 2007-10-10 Intercell AG Modifizierte peptide enthaltende pharmazeutische präparationen
WO2002022155A1 (en) * 2000-09-13 2002-03-21 Hawaii Biotechnology Group, Inc. Immunogenic composition of hepatitis c and methods of use thereof
US20030148261A1 (en) * 2001-03-12 2003-08-07 Erol Fikrig Compositions and methods comprising West Nile virus polypeptides
CU23245A1 (es) 2001-07-16 2007-10-17 Inst De Medicina Tropical Pedr CADENAS QUIMéRICAS CODIFICANTES PARA PROTEINAS INDUCTORAS DE EFECTOS CONTRA VIRUS. PREPARADOS UTILIZANDO PROTEINAS QUIMéRICAS
AU2003205169A1 (en) * 2002-01-15 2003-07-30 Acambis, Inc. Viral vaccine production method
AU2003267943C1 (en) * 2002-02-26 2009-05-21 Altravax, Inc. Novel flavivirus antigens
AU2003263853A1 (en) * 2002-08-16 2004-03-03 Board Of Regents The University Of Texas System Compositions and methods related to flavivirus envelope protein domain iii antigens
AU2003301804A1 (en) * 2002-11-05 2004-06-07 Institut National De La Sante Et De La Recherche Medicale Dc-sign blockers and their use for preventing or treating viral infections.
WO2004052293A2 (en) * 2002-12-11 2004-06-24 Hawaii Biotech, Inc. Recombinant vaccine against flavivirus infection
US20050287170A1 (en) * 2002-12-11 2005-12-29 Hawaii Biotech, Inc. Subunit vaccine against West Nile viral infection
WO2005035771A2 (en) * 2003-10-10 2005-04-21 Powderject Vaccines, Inc. Nucleic acid constructs
US20070269461A1 (en) * 2004-01-04 2007-11-22 Sudhanshu Vrati Recombinant Vaccine Against Japanese Encephalitis Virus (Jev) Infection and a Method Thereof
US8900644B2 (en) * 2004-12-22 2014-12-02 Colgate-Palmolive Company Oral care compositions containing compounds from magnolia and hops extracts
CU23578A1 (es) 2005-09-16 2010-09-30 Ct Ingenieria Genetica Biotech Proteína de la cápsida del virus dengue inductora de respuesta protectora y composición vacunal
CU23630A1 (es) 2006-10-30 2011-02-24 Ct Ingenieria Genetica Biotech Moléculas peptídicas quiméricas con propiedades antivirales contra los virus de la familia flaviviridae
US8835620B2 (en) * 2008-01-11 2014-09-16 Vgx Pharmaceuticals, Llc Vaccines against multiple subtypes of dengue virus
JP2012528791A (ja) 2009-05-31 2012-11-15 メルク・シャープ・エンド・ドーム・コーポレイション ヒト防御用組換えサブユニット西ナイルウイルスワクチン
US8999675B2 (en) 2009-08-31 2015-04-07 Gen-Probe Incorporated Dengue virus assay
WO2012027473A2 (en) * 2010-08-24 2012-03-01 The University Of North Carolina At Chapel Hill Immunogenic compositions comprising alphavirus vectored dengue virus e protein antigens
KR20130138789A (ko) 2010-10-29 2013-12-19 머크 샤프 앤드 돔 코포레이션 재조합 서브유닛 뎅기 바이러스 백신
CA3166063A1 (en) 2013-03-15 2014-09-25 Takeda Vaccines, Inc. Compositions and methods for dengue virus chimeric constructs in vaccines
WO2018022790A1 (en) 2016-07-27 2018-02-01 Hawaii Biotech Inc. Optimized zika virus envelope gene and expression thereof
US11464815B2 (en) 2018-09-05 2022-10-11 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
IL298307A (en) 2018-09-05 2023-01-01 Takeda Vaccines Inc Dengue fever vaccine unit dose and its administration
US11426461B2 (en) 2018-09-05 2022-08-30 Takeda Vaccines, Inc. Methods for preventing dengue and hepatitis A

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0768267B2 (ja) * 1986-06-05 1995-07-26 財団法人阪大微生物病研究会 フラビウイルス抗原
US5013652A (en) * 1986-10-14 1991-05-07 Genex Corporation Composite yeast vectors
IL91304A0 (en) * 1988-08-20 1990-03-19 Us Health Recombinant vaccinia virus for prevention of disease caused by flavivirus
FR2665710A1 (fr) * 1990-08-10 1992-02-14 Pasteur Institut Baculovirus recombinant exprimant les proteines e et ns1 de virus appartenant aux flaviviridae ou de virus apparentes aux flaviviridae, applications diagnostiques et therapeutiques.
MY109299A (en) * 1990-08-15 1996-12-31 Virogenetics Corp Recombinant pox virus encoding flaviviral structural proteins
US5514375A (en) * 1990-08-15 1996-05-07 Virogenetics Corporation Flavivirus recombinant poxvirus vaccine
US5494671A (en) * 1990-08-27 1996-02-27 The United States Of America As Represented By The Department Of Health And Human Services C-terminally truncated dengue and Japanese encephalitis virus envelope proteins
WO1992003161A1 (en) * 1990-08-27 1992-03-05 The United States Of America, Represented By The Secretary, United States Department Of Commerce Flavivirus envelope proteins with increased immunogenicity for use in immunization against virus infection

Also Published As

Publication number Publication date
EP0836482B1 (de) 2002-11-13
DK0836482T3 (da) 2003-02-17
CA2224724A1 (en) 1996-11-28
CA2224724C (en) 2007-12-04
US6165477A (en) 2000-12-26
DE69624815T2 (de) 2003-07-10
WO1996037221A1 (en) 1996-11-28
DE69624815D1 (de) 2002-12-19
AU716676B2 (en) 2000-03-02
AU6023996A (en) 1996-12-11
PT836482E (pt) 2003-02-28
EP0836482A1 (de) 1998-04-22
ES2184869T3 (es) 2003-04-16
EP0836482A4 (de) 1999-09-01

Similar Documents

Publication Publication Date Title
ATE227584T1 (de) Untereinheitsimpfstoff gegen flavivirus infektion
Rey et al. The envelope glycoprotein from tick-borne encephalitis virus at 2 Å resolution
DK0604566T3 (da) Kimærisk og/eller vækstbegrænsede flavivirus
WO1999006068A3 (en) Recombinant dimeric envelope vaccine against flaviviral infection
US8153360B2 (en) Flavivirus fusion inhibitors
GB2269820A (en) Flavivirus recombinant poxvirus vaccine
RU2218403C2 (ru) Генетически модифицированный, покрытый мембраной вирусный вектор
WO2004076619A3 (en) New dengue and west nile viruses proteins and genes coding the foregoing, and their use in vaccinal, therapeutic and diagnostic applications
RU2000107129A (ru) Химерическая вакцина против вируса клещевого энцефалита
JP2003525564A5 (de)
Flamand et al. Expression and secretion of Japanese encephalitis virus nonstructural protein NS1 by insect cells using a recombinant baculovirus
EP2462930B1 (de) Herbeiführung einer Immunreaktion gegen das Dengue-Virus mithilfe des Prime-Boost-Verfahrens
EP3498850A1 (de) Heterologe expressionskassette, dna-konstrukt und impfstoffzusammensetzung zur immunisierung gegen flavivirus und/oder andere pathogene
BR9611477A (pt) Polipeptìdeo ou glicopeptìdeo, composições aptas a estimular a imunidade, sequência, e vetor, de ácidos nucleicos, vetor de expressão, processo de preparação de um polipeptìdeo ou glicopeptìdeo, vacina polivalente contr5a o vìrus da dengue e composição antigênica
Hill et al. The Cellular Immune Response
Venugopal et al. Immunity to St. Louis encephalitis virus by sequential immunization with recombinant vaccinia and baculovirus derived PrM/E proteins
WO2022104081A3 (en) Modified secreted hepatitis c virus (hcv) e1e2 glycoproteins and methods of use thereof
FI953581A0 (fi) Tick-Borne Enzephalitis (TBE) -viruksen infektoiva cDNA-klooni, siitä johdettu yhdistelmärokote ja sen valmistus
WO2007103565A3 (en) Wnv dna vaccine incorporating a cmv/r backbone and expressing wnv prm and e proteins
MXPA98003840A (en) Vaccine polivalent anti-den
PJGACHEV et al. Double-Subgenomic Sindbis Virus Recombinants Expressing Immunogenic Proteins of Japanese Encephalitis Virus lnduce Significant Protection in Mice against Lethal JEV Infection
Kelly et al. Recombinant vaccine against dengue virus
HK1156632A (en) Flavivirus fusion inhibitors
TH64126B (th) วัคซีนต้านไวรัสไข้สมองอักเสบและเวสต์ไนล์ไวรัส
HK1168359A (en) Flavivirus fusion inhibitors

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0836482

Country of ref document: EP